The goal was never "stability" Buckland, it was to develop a medication that would slow the progress of this (MND's) aggressive progress. If one patient is showing apparent stability and it's proven to be caused by the monepantel treatment, then that was an unexpected bonus. Stop trolling.
Ann: PharmAust MND Trial Interim Analysis PK Outcomes, page-101
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $89.95M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 18.5¢ | $79.24K | 426.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 100404 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 58956 | 1 |
View Market Depth
| Last trade - 12.44pm 30/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |